RSV vaccine study tests multidose vial safety
NCT ID NCT06473519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an RSV vaccine in 453 healthy women aged 18-49. It compared a multidose vial with a preservative to a single-dose vial without one. The goal was to see if both versions are safe and produce a similar immune response. Participants received one shot and were followed for about 6 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Atlanta
Stockbridge, Georgia, 30281, United States
-
Clinical Research Prime
Idaho Falls, Idaho, 83404, United States
-
Clinical Research Prime Rexburg
Rexburg, Idaho, 83440, United States
-
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas, 78229, United States
-
Headlands Research - Detroit
Southfield, Michigan, 48034, United States
-
Qps-Mra, Llc
South Miami, Florida, 33143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies